Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/28/24 | SEC-generated letter |
|
1 | ||
| 10/24/24 | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
5 | ||
| 10/22/24 | Registration statement for specified transactions by certain issuers |
|
28 | ||
| 10/17/24 | Prospectus filed pursuant to Rule 424(b)(5) |
|
53 | ||
| 10/17/24 | Current report filing |
|
 |
41 | |
| 10/16/24 | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | ||
| 10/16/24 | Notice of Effectiveness |
|
1 | ||
| 10/16/24 | Prospectus filed pursuant to Rule 424(b)(5) |
|
52 | ||
| 10/16/24 | Current report filing |
|
|
4 | |
| 10/16/24 | Registration statement for specified transactions by certain issuers |
|
41 |